Citation

Wysowski DK, Baum C, Ferguson WJ, Lundin F, Ng MJ, Hammerstrom T. J. Clin. Epidemiol. 1996; 49(1): 111-113.

Affiliation

Office of Epidemiology and Biostatistics, Food and Drug Administration, Rockville, Maryland, USA.

Copyright

(Copyright © 1996, Elsevier Publishing)

DOI

unavailable

PMID

8598503

Abstract

A retrospective cohort study was conducted in individuals 65 years of age and older using Medicaid-reimbursed claims to assess the risk of hip fracture in users of two sedative-hypnotic drugs, triazolam and temazepam. Using the triazolam cohort as the referent group, the rate ratio was 0.92 (95% confidence interval, 0.72 to 1.17) for hip fracture with temazepam. Stratifying by age, sex, race, residence, time enrolled in Medicaid, prescription number, combinations of these, and several other potential confounding variables did not materially change the results. Compared with the short-acting benzodiazepine hypnotic temazepam, use of triazolam, an ultra-short-acting benzodiazepine hypnotic, did not decrease the risk of hip fracture. This study did not determine that either drug, compared with no use in an insomniac control group, increases the risk of hip fracture. However, because sedative-hypnotic drugs have been found in other studies to increase the risk of falling and hip fracture, they should be used with caution, especially in the elderly.

Language: en